The use of monoclonal antibodies in multiple sclerosis (MS) patients is in a 
transitional period. Studies regarding well-established, effective antibodies 
such as natalizumab and alemtuzumab focus more and more on long-term efficacy 
and safety, risk management, and treating complications. Primary progressive MS, 
a disease that was long considered to be unmodifiable, is currently in focus 
following ocrelizumab being approved as the first drug with a proven beneficial 
effect on the disease course. Conversely, post-marketing safety mechanisms have 
also proven to function as daclizumab has been suspended after a series of 
relevant serious adverse events. Currently, new therapies are emerging that 
promise more convenience and an improved safety profile (ofatumumab) or 
remyelinating potential with clinical improvement (opicinumab). While it is very 
unlikely that monoclonal antibodies will ever cure MS, they have become very 
valuable therapeutic tools to better patient outcomes. This review focuses on 
developments of monoclonal antibodies used in the past, present, and near future 
in MS patients.